Sun Pharma, Glenmark recall products in US due to manufacturing issues - Business Standard

Leading drug makers Sun Pharma and Glenmark are recalling products in the US, the world's largest market for medicines, due to lapses in the manufacturing process.

As per the latest enforcement report by the US Food and Drug Administration (USFDA), a US-based unit of Sun Pharma is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market.

According to the US health regulator, the Mumbai-based drug major is recalling the affected lot due to "water leakage" leading to deviation from current good manufacturing practices (cGMP).

The company is also recalling 27 vials of the same medication due to cGMP deviations, USFDA said.

"Manufacturing deviations were reported due to an abnormal appearance on parts of machinery," it added. The affected lot was produced at Sun Pharma's Halol (Gujarat) based manufacturing plant.

New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, initiated the Class II nationwide (US) recall of the affected lots last month.

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Mumbai-headquartered Glenmark, on the other hand is recalling 98,307 packs of Mometasone Furoate Topical Solution, a medication used to treat skin conditions such as eczema, psoriasis, allergies, and rash.

New Jersey-based Glenmark Pharmaceuticals Inc is recalling the lot, which rolled out from the company's Baddi (Himachal Pradesh) plant, due to "Defective Container", the USFDA stated.

The company initiated the nationwide recall, which the US health regulator classified as Class III, on June 16.

A Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."

The US generic drug market was estimated to be around USD 115.2 billion in 2019.

It is by far the largest market for pharmaceutical products in the world.

In the last financial year, India's pharma exports stood at around USD 24.62 billion with the US, the UK, South Africa, Russia, and Nigeria emerging as the top five destinations.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Adblock test (Why?)